Drug Pipeline Database & Screener

Over 2000 drug entries from about 550 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

NASDAQ and NYSE stocks only are shown. OTC stocks are not covered on BioPharmCatalyst.

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates.

Financial data are delayed 15-25 minutes.

Showing companies
Screener
Sort
Stage
Indication
Market Cap
Price
Short ratio
Relative Volume
Price to book
Company
Price
Change
No of Shares
Market Cap
Short Ratio
Updated
$75.39
-0.34  -0.45%
1.5 billion
$111.3 billion
6.62
04/07/2020
Tap to view 46 drugs
Drug Indication Stage News
Depatuxizumab mafodotin ABT-414 Glioblastoma (rGBM) Phase 3 Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.
Veliparib Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) Phase 3 Phase 3 trial did not meet primary endpoints - April 19, 2017.
Ibrutinib Relapsed or refractory MCL mantle cell lymphoma Approved Approved November 13, 2013.
Imbruvica Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy Approved Approved February 12, 2014.
Imbruvica Deletion 17p Approved Approved July 19, 2014.
VIEKIRA PAK HCV - genotype 1 Approved Approved December 19, 2014.
IMBRUVICA Waldenström’s Macroglobulinemia Approved Approved January 29, 2015 - PCYC
ABBV-8E12 Alzheimer's disease Phase 2 Phase 2 initiation announced January 25, 2017.
Venclexta (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) Approved Approval announced June 11, 2018.
Venetoclax - CANOVA Relapsed or refractory multiple myeloma Phase 3 Phase 3 data due in 2021.
Risankizumab Psoriasis Approved FDA approval announced April 23, 2019.
Imbruvica Second-line Chronic graft-versus-host disease (GVHD) Approved Approval announced August 2, 2017.
ABT-494 Psoriatic Arthritis Phase 3 Phase 3 trial to commenced 2017.
Rova-T (TRINITY) Third-line Small Cell Lung Cancer Phase 2 Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
Upadacitinib Atopic Dermatitis Phase 3 Phase 3 trial met primary and secondary endpoints - October 31, 2019.
Imbruvica Marginal zone lymphoma Approved sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV) Approved Approval announced August 3, 2017.
Elagolix Uterine Fibroids PDUFA NDA filing announced August 5, 2019. PDUFA date 2Q 2020. Exact date not provided. Estimate June 4, 2020 based on 10-month timeline.
Elagolix Endometriosis Approved FDA approval announced July 24, 2018.
ABT-494 upadacitinib Rheumatoid arthritis Approved FDA Approval announced August 16, 2019.
Rova-T (TAHOE) Second-line Small Cell Lung Cancer Phase 3 Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (MERU) First-line Small Cell Lung Cancer Phase 3 Phase 3 trial demonstrated no survival benefit at interim analysis - October 29, 2019.
Imbruvica and Gazyva - iLLUMINATE Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) Approved FDA approval announced January 28, 2019.
IMBRUVICA (ibrutinib) Waldenström’s Macroglobulinemia Approved FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib) Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Venclexta First line unfit AML Approved FDA approval announced November 21, 2018.
Upadacitinib - U-ACHIEVE Ulcerative colitis Phase 2/3 Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Venetoclax and obinutuzumab Chronic Lymphocytic Leukemia Phase 3 FDA approval announced May 15, 2019.
Ibrutinib (Imbruvica) Pancreatic cancer Phase 3 Phase 3 primary endpoint not met (PFS/OS).
Venclexta plus Gazyva Chronic lymphocytic leukemia (CLL) Phase 3 Phase 3 data presented at ASCO June 4, 2019. HR 0.35. CRR 49.5%. ORR 84.7% vs. 71.3%.
Venclexta BELLINI Multiple myeloma Phase 3 Phase 3 primary endpoint met.
Venetoclax and obinutuzumab Chronic lymphocytic leukemia sNDA Filing sNDA filing announced June 4, 2019.
Veliparib Ovarian cancer Phase 3 Phase 3 presentation at ESMO 28 September 2019.
Risankizumab ( LIMMITLESS ) Psoriasis Phase 3 Phase 3 data presented at EADV October 10, 2019.
IMBRUVICA (ibrutinib) and rituximab Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). sNDA Filing sNDA filing announced November 8, 2019.
Risankizumab vs secukinumab Plaque psoriasis Phase 3 Phase 3 trial met primary endpoint - January 14, 2020.
Venetoclax - Viale-C Treatment-naïve Acute Myeloid Leukemia Phase 3 Phase 3 trial did not meet primary endpoint - February 28, 2020.
Upadacitinib - SELECT-NEXT Psoriatic arthritis sNDA Filing Phase 3 primary endpoint met - February 5, 2020. sNDA filing due 2Q 2020.
Risankizumab MOTIVATE Crohn’s Disease Phase 3 Phase 3 data due 2020.
Risankizumab KEEPSAKE2 Psoriatic Arthritis Phase 3 Phase 3 data due 2020.
Risankizumab vs secukinumab Psoriasis Phase 3 Phase 3 data due 2020.
Upadacitinib Atopic dermatitis Phase 3 Phase 3 data due 2020.
Venclexta (VIALE-A) Acute Myeloid Leukemia (AML) Phase 3 Phase 3 trial met dual primary endpoints of overall survival and composite complete remission rate - March 23, 2020.
Imbruvica + Venclexta (CAPTIVATE) Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma Phase 2 Phase 2 data due 2020.
Ibrutinib in combination with prednisone Chronic Graft Versus Host Disease Phase 3 Phase 3 data due 2020.
ABBV-951 Parkinson's disease Phase 3 Phase 3 data due 2021.
$2.30
+0.01  +0.44%
83.6 million
$192.3 million
04/07/2020
Tap to view 4 drugs
$2.76
-0.07  -2.65%
1.6 million
$4.4 million
04/07/2020
Tap to view 1 drug
Drug Indication Stage News
Gencaro Chronic Heart Failure Phase 3 Phase 3 trial to be initiated 4Q 2020 subject to financing.
$1.04
  +0.00%
70.1 million
$72.9 million
04/07/2020
Tap to view 4 drugs
Drug Indication Stage News
ARB-1467, tenofovir, and pegylated interferon Hepatitis B (HBV) Phase 2 Phase 2 trial ongoing but no plans to continue further development.
AB-452 Hepatitis B Phase 1 Program to be discontinued - February 10, 2020.
AB-506 Hepatitis B (HBV) Phase 1 Development to be discontinued - noted October 3, 2019.
AB-729 Hepatitis B (HBV) Phase 1 Phase 1a/b multiple dose cohort data expected in 2H 2020
$41.71
-1.58  -3.65%
155.3 million
$6.5 billion
04/07/2020
Tap to view 7 drugs
Drug Indication Stage News
Pimavanserin - CLARITY-2 Adjunctive Treatment in Patients With Major Depressive Disorder Phase 3 Phase 3 data due 4Q 2020.
Pimavanserin - Advance Adjunctive treatment in patients with negative symptoms of schizophrenia Phase 2 Phase 2 data released November 25, 2019. Primary endpoint met. Key secondary missed. Further pivotal trial to be initiated 2H 2020.
Pimavanserin - Enhance Adjunctive treatment of schizophrenia Phase 3 Phase 3 data did not meet primary endpoint - July 22, 2019.
Pimavanserin - SERENE Alzheimer’s disease agitation Phase 2 Announced October 4, 2017 that trial will be discontinued.
Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin - Harmony Alzheimer’s disease psychosis sNDA Filing Phase 3 trial stopped early after meeting primary endpoint - September 9, 2019. sNDA filing due summer 2021.
Trofinetide Rett Syndrome Phase 3 Phase 3 data due 2021.
$1.90
-0.14  -6.86%
10.1 million
$19.2 million
04/07/2020
Tap to view 4 drugs
Drug Indication Stage News
EDSIVO Vascular Ehlers-Danlos Syndrome CRL CRL issued June 25, 2019.
Tovaxin (Tcelna) Secondary Progressive MS (SPMS) Phase 2b Phase 2b trial did not meet primary endpoint - October 28, 2016.
ACER-001 Urea cycle disorder (UCD) NDA Filing NDA filing due early 2021.
Osanetant induced Vasomotor Symptoms (iVMS) Phase 1/2 Phase 1/2 trial to be initiated mid-2020.
$0.33
  +-0.76%
31.4 million
$10.3 million
04/07/2020
Tap to view 1 drug
Drug Indication Stage News
Cytisine Smoking cessation Phase 3 Phase 3 trial to be initiated 1H 2020.
$6.81
-0.43  -5.94%
71.9 million
$489.4 million
04/07/2020
Tap to view 9 drugs
Drug Indication Stage News
Crenezumab - CREAD 2 Alzheimer’s disease Phase 3 Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
RG6100 (Anti-Tau RO7105705) Alzheimer’s disease Phase 2 Phase 2 primary completion 2Q 2020.
ACI-24 (anti-Abeta vaccine) Alzheimer's disease-like characteristics in individuals with Down syndrome Phase 1/2 Phase 1/2 interim data released July 2019.
Crenezumab - CREAD 1 Alzheimer’s disease Phase 3 Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
MTAU9937A Alzheimer’s disease Phase 2 Phase 2 trial initiation announced February 20, 2019.
ACI-35 Alzheimer’s disease Phase 1b Phase 2 trial planned for 1H 2019.
ACI-3024 Alzheimer’s disease Phase 1 Phase 1 data due 2H 2020.
ACI-35.030 Alzheimer’s Disease Phase 1/2 Phase 1b/2 interim analysis 2Q 2020.
ACI-24 Alzheimer’s disease (AD) Phase 2 Phase 2 12-month analysis due 2H 2020.
$1.12
-0.03  -2.61%
41.5 million
$46.5 million
04/07/2020
Tap to view 9 drugs
Drug Indication Stage News
ATI-502 (ATI-50002-AA-201) - dose ranging Alopecia areata Phase 2 Phase 2 data did not meet primary endpoint - June 26, 2019.
ATI-502 (VITI-201 Topical) Vitiligo Phase 2 Development to be discontinued - noted August 8, 2019.
ATI-501 (AUAT-201 Oral) Alopecia areata Phase 2 Phase 2 data met primary endpoint and some secondary endpoints - July 30, 2019. Partner required for further development.
ESKATA (hydrogen peroxide) Seborrheic keratosis (SK) Approved Approval announced December 15, 2017.
A-101 THWART-1 and THWART-2 Common warts (verruca vulgaris) Phase 3 Phase 3 data met all endpoints - September 16, 2019 and October 24, 2019.
ATI-502 Androgenetic alopecia (AGA) - Hair loss Phase 2 Partner required to further development.
ATI-502 (AD-201 Topical) Atopic dermatitis (AD) Phase 2 Phase 2 trial completed.
ATI-450 Rheumatoid arthritis (RA) Phase 1/2 Phase 2 trial to be initiated 1H 2020.
ATI-1777 Atopic dermatitis Phase 1/2 Phase 1/2 trial to be initiated 2H 2020.
$1.28
-0.01  -0.78%
80.4 million
$102.9 million
04/07/2020
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
DSUVIA (ARX-04) Moderate-to-severe acute pain following a surgical procedure Approved FDA Approval announced November 2, 2018.
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. NDA resubmission planned.
$0.36
  +0.48%
90.2 million
$32.2 million
04/07/2020
Tap to view 1 drug
Drug Indication Stage News
CaPre (TRILOGY 1 and 2) Hypertriglyceridemia Phase 3 Phase 3 TRILOGY 1 data did not meet primary endpoint - January 13, 2020. TRILOGY 2 data due 3Q 2020.
$2.83
-0.17  -5.67%
130.1 million
$368.1 million
04/07/2020
Tap to view 5 drugs
Drug Indication Stage News
MAGE-A4 (ADP-A2M4) Soild tumors Phase 1 Phase 1 summary at conference 1H 2020. 12-month durability data from patients with synovial sarcoma due 2H 2020.
AFP (ADP-A2AFP) Hepatocellular carcinoma Phase 1 Phase 1 safety and cohort 3 update due 1H 2020. Expansion cohort data due 2H 2020.
MAGE-A10 (ADP-A2M10) Non-Small Cell Lung Cancer (NSCLC) Phase 1 Phase 1 enrolment completed 2019.
MAGE-A4 (SPEARHEAD‑1) Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) Phase 2 Phase 2 data due 2021.
MAGE-A4 (ADP-A2M4CD8 - SURPASS) Soild tumors Phase 1 Phase 1 dose escalation cohort update due 2H 2020.
$1.23
-0.01  -0.81%
10.5 million
$12.9 million
04/07/2020
Tap to view 1 drug
$2.94
-0.24  -7.55%
86.3 million
$253.9 million
04/07/2020
Tap to view 2 drugs
Drug Indication Stage News
ASCENIV (RI-002) Primary Immune Deficiency Diseases Approved FDA Approval announced April 1, 2019.
BIVIGAM Primary humoral immunodeficiency CRL Response to Complete Response Letter submitted January 7, 2019.
$0.36
-0.01  -3.30%
73.7 million
$26.4 million
04/07/2020
Tap to view 5 drugs
Drug Indication Stage News
Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. Approved CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
APC-1000 Asthma/COPD Phase 2 Phase 3 development on hold - noted May 9, 2019.
Symjepi - low dose Anaphylaxis Approved FDA Approval announced September 27, 2018.
Higher Dose Naloxone Injection Opioid overdose NDA Filing CRL announced November 25, 2019. NDA to be refiled 2Q 2020.
APC-8000 (sublingual tadalafil) Erectile dysfunction NDA Filing Refusal to file letter received February 26, 2019.
$2.84
-0.01  -0.35%
28 million
$79.6 million
04/07/2020
Tap to view 5 drugs
Drug Indication Stage News
ADS-4101 Partial onset seizures in patents with epilepsy Phase 1b Further development deferred - noted May 9, 2019.
GOCOVRI (amantadine) Multiple sclerosis (MS) Phase 3 Phase 3 data met primary endpoint at one of two doses. Secondary endpoint in walking impairment not met. Second trial will not be initiated as a result of data - December 17, 2019.
Namzaric Moderate to severe dementia of the Alzheimer's type. Approved Approved December, 24 2014.
ADS-5102 Levodopa-Induced Dyskinesia Approved Approval announced August 24, 2017.
GOCOVRI (amantadine) Dyskinesia patients with Parkinson's disease Phase 3 Phase 3 open-label data released April 19, 2018.
$2.49
-0.38  -13.24%
80.8 million
$201.1 million
04/07/2020
Tap to view 6 drugs
Drug Indication Stage News
CRS-207 and GVAX Pancreas - ECLIPSE trial Pancreatic cancer Phase 2b Phase 2b primary endpoint not met - May 2016
ADU-S100 and Spartalizumab Solid tumors or lymphomas Phase 1b Phase 1 trial to be discontinued - noted December 17, 2019.
ADU-S100 and ipilimumab Melanoma Phase 1 Phase 1 enrolment to be terminated - noted December 17, 2019.
BION-1301 IgA Nephropathy Phase 1 Phase 1 data due 1H 2020 in healthy volunteers and 2H 2020 in IgA Nephropathy patients.
ADU-S100 and pembrolizumab Squamous Cell Carcinoma of the Head and Neck (SCCHN) Phase 2 Phase 2 data due 2H 2020.
MK-5890 and pembrolizumab Non-small cell lung cancer (NSCLC) Phase 2 Phase 2 trial has been initiated - noted February 6, 2020.
$9.86
-0.11  -1.10%
79.7 million
$785.7 million
04/07/2020
Tap to view 3 drugs
Drug Indication Stage News
ADVM-043 Alpha-1 Antitrypsin (A1AT) Deficiency Phase 1/2 Development to be discontinued - noted November 1, 2018.
AVA-101 Wet age-related macular degeneration (Wet-AMD) Phase 2a Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
ADVM-022 (OPTIC) Wet age-related macular degeneration (Wet-AMD) Phase 1 Phase 1 updated data due at ARVO May 4, 2020 8:15 – 8:30 a.m. ET.
$0.62
-0.01  -2.22%
60.2 million
$37.1 million
04/07/2020
Tap to view 7 drugs
Drug Indication Stage News
Axalimogene filolisbac + durvalumab Recurrent or refractory HPV-associated cervical cancer and head & neck cancer Phase 1/2 Enrollment to be terminated - noted November 2, 2018.
ADXS-PSA and Keytruda - KEYNOTE-046 Castrate-resistant prostate cancer Phase 1/2 Phase 1 presentation at ASCO Genitourinary Cancers Symposium February 13, 2020 noted median overall survival (95% CI) of 33.7 months.
Axalimogene filolisbac - AIM2CERV Trial High-risk, locally advanced cervical cancer Phase 3 Phase 3 trial closed - noted June 27, 2019.
ADXS-HER2 HER2-driven malignancies - cancer Phase 1b Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
Axalimogene filolisbac Anal cancer (FAWCETT) Phase 2 Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
ADXS-NEO Non-small cell lung cancer (NSCLC) Phase 1 Phase 1 safety and immunogenicity data presented at AACR March 2019
ADXS-HOT 503 Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1 data noted 50% (3 of 6) of evaluable patients from monotherapy arm and 1/1 patients on combo arm (Keytruda) showed stable disease - February 20, 2020.
$12.71
+0.71  +5.92%
46.4 million
$590.1 million
04/07/2020
Tap to view 6 drugs
Drug Indication Stage News
Roclatan Glaucoma Approved FDA Approval announced March 12, 2019.
Rhopressa Glaucoma Approved PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
AR-13503 Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) Phase 1/2 Phase 1/2 trial initiation announced August 20, 2019.
AR-1105 Macular edema due to RVO (retinal vein occlusion) Phase 2 Phase 2 top-line data due later in 2020.
Roclatan - Mercury 3 Open Angle Glaucoma Phase 3 Phase 3 top-line data due 2H 2020.
AVX-012 Dry eye disease Phase 2b Phase 2b trial to be initiated late-2020.
$0.71
-0.03  -3.40%
20 million
$16.7 million
04/07/2020
Tap to view 2 drugs
Drug Indication Stage News
Macimorelin Acetate - Macrilen Adult Growth Deficiency Approved CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Zoptrex Endometrial cancer Phase 3 Phase 3 trial did not meet primary endpoint - May 1, 2017.
$1.78
-0.04  -2.47%
76.2 million
$135.7 million
04/07/2020
Tap to view 5 drugs
Drug Indication Stage News
AFM13 with Keytruda Hodgkin Lymphoma - Cancer Phase 1b Phase 1b updated data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%.
AFM13 Hodgkin Lymphoma - Cancer Phase 2 Phase 2a ongoing.
AFM13 CD30-positive peripheral T cell lymphoma (PTCL) Phase 2 Phase 2 dosing has been initiated - noted November 19, 2019.
AFM11 Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) Phase 1 Phase 1 program terminated - noted May 22, 2019.
AFM24 EGFR-expressing solid tumors Phase 1/2 Phase 1/2a trial to commence 1Q 2020.
$2.38
-0.09  -3.64%
161.6 million
$384.6 million
04/07/2020
Tap to view 5 drugs
Drug Indication Stage News
Balstilimab (anti-PD-1) and zalifrelimab (anti-CTLA-4) Solid tumors BLA Filing BLA filing due 2020. Data February 20, 2020 noted 20.6% overall response rate (ORR), which included a complete response (CR) rate of 8.8% in second-line cervical cancer - Data February 20, 2020.
Zalifrelimab - AGEN1884 (anti-CTLA-4) Solid cancers Phase 1/2 Phase 1/2 ongoing.
Shingrix Shingles Approved Approval announced October 20, 2017.
Balstilimab (AGEN2034) anti-PD-1 Cervical cancer BLA Filing Phase 1 data from interim analysis noted ORR of 11.4% - February 20, 2020. BLA filing 2020.
AGEN1181 - 2nd gen CTLA Advanced cancer Phase 1 Phase 1 data presented at Investor Day February 20, 2020.
$38.18
-1.32  -3.34%
68.5 million
$2.6 billion
04/07/2020
Tap to view 19 drugs
Drug Indication Stage News
AG-348 - Mitapivat Thalassemia Phase 2 Phase 2 updated data due at EHA June 11 - 14, 2020.
Ivosidenib IDH1m Relapsed/Refractory AML - cancer Approved FDA Approval announced July 20, 2018.
AG-348 (ACTIVATE-T) Pyruvate kinase deficiency Phase 3 Phase 3 data due by end of 2020.
AG-120 and VIDAZA - AGILE Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 enrolment to be completed 2020.
Enasidenib (AG-221) - IDHENTIFY Refractory Acute myeloid leukemia (AML) - cancer Phase 3 Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
IDHIFA (enasidenib) - AG-221 Advanced hematologic malignancies with an IDH2 mutation Approved Approval announced August 1, 2017.
AG-120 Ivosidenib (ClarIDHy) IDH1 mutant positive cholangiocarcinoma - cancer Phase 3 sNDA filing due to be filed following final overall survival analysis by end of 2020.
AG-120 Ivosidenib R/R Acute Myeloid Leukemia (AML) Phase 1 Phase 1 data at ASCO June 2018 noted CR rate was 24%.
Enasidenib or ivosidenib with VIDAZA Frontline AML with IDH1 or IDH2 mutation Phase 1/2 Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%.
Ivosidenib or enasidenib Frontline AML with IDH1 or IDH2 mutation Phase 1 Phase 1 updated data at ASH December 2018. CR+CRi/CRp 80%.
AG-270 Solid tumors Phase 1 Phase 1 data presented at AACR-NCI-EORTC October 27, 2019. Trial is ongoing.
Vorasidenib (AG-881) Glioma Phase 3 Phase 3 trial to be initiated YE 2019.
Ivosidenib Frontline AML with IDH1 mutation Approved FDA Approval announced May 2, 2019.
Ivosidenib and Vorasidenib (AG-881) IDHm low-grade glioma Phase 1 Phase 1 updated data noted 31% ORR with postoperative treatment - November 22, 2019.
Ivosidenib IDH1 mutant newly diagnosed AML ineligible for standard therapies Phase 1 Phase 1 updated data at ASCO June 3, 2019. 30% CR rate.
Ivosidenib and azacitidine ( Vidaza) Newly diagnosed AML with an IDH1 mutation Phase 1 Phase 1 updated data at ASH December 9, 2019 noted complete response (CR) rate of 61% and a CR + CR with partial hematologic recovery (CRh) rate of 70%.
AG-348 - Mitapivat (ACTIVATE) Pyruvate Kinase Deficiency Phase 3 Phase 3 data due by the end of 2020.
AG-348 - Mitapivat Sickle cell disease. Phase 1 Phase 1 data due mid-2020.
AG-946 Healthy volunteers Phase 1 Phase 1 trial to commence mid-2020.
$4.85
-0.01  -0.21%
29.1 million
$141.1 million
04/07/2020
Tap to view 6 drugs
Drug Indication Stage News
AEB1102 Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS) Phase 1 Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
Pegzilarginase (AEB1102) Arginase I deficiency Phase 3 Phase 3 data due 1Q 2021.
AEB1102 Solid tumors Phase 1 Phase 1 dose escalation data presented at AACR April 15, 2018.
Pegzilarginase (AEB1102) Solid tumors Phase 1 Phase 1 data presented at ESMO October 2018 noted 1/28 PRs and 8/23 SD.
Pegzilarginase (AEB1102) + KEYTRUDA Small cell lung cancer (SCLC) Phase 2 Phase 1/2 trial ongoing.
ACN00177 Homocystinuria Phase 1/2 Phase 1/2 trial to be initiated 2Q 2020 with initial data due 1Q 2021.
$178.26
+0.11  +0.06%
329 million
$58.6 billion
3.88
04/07/2020
Tap to view 28 drugs
Drug Indication Stage News
Botox Forehead lines Approved Approval (third indication) announced October 3, 2017.
RTGel in combination with BOTOX Overactive Bladder (OAB) Phase 2 Phase 2 trial ongoing.
JUVÉDERM VOLLURE Correction of moderate to severe facial wrinkles and folds Approved Approval announced March 20, 2017.
Botox Depression Phase 2 Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
RORγt agonist Psoriasis Phase 2b Phase 2b trial ongoing.
Cariprazine Maintenance Treatment of Schizophrenia Approved Approval announced November 13, 2017.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma BLA Filing BLA filing announced December 19, 2019.
ATOGEPANT Chronic migraine Phase 3 Phase 3 data due in 2020.
RAPASTINEL Major depressive disorder (MDD) Phase 3 Phase 3 trials did not meet primary endpoints - March 6, 2019.
RELAMORELIN Diabetic Gastroparesis Phase 3 Phase 3 top-line data due 2020.
ESMYA (ulipristal acetate) Uterine Fibroids CRL CRL issued August 21, 2018.
ABICIPAR Diabetic macular edema (DME) Phase 3 Phase 3 trial to be initiated 2019.
Cenicriviroc (CVC) Nonalcoholic steatohepatitis (NASH) Phase 3 Phase 3 data due 2021.
ABICIPAR Age-related macular degeneration (AMD) PDUFA priority review BLA acceptance of filing announced September 9, 2019. Estimated PDUFA date July 9, 2020.
AVYCAZ (ceftazidime and avibactam) Complicated Urinary Tract Infections (cUTI) Approved sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
Oxymetazoline HCl cream 1.0% Facial Erythema (Redness) Associated with Rosacea Approved Approved January 19, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults Chronic idiopathic constipation (CIC) Approved sNDA approval announced January 26, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) Approved Approved September 14, 2017.
Sarecycline Severe acne vulgaris Approved FDA Approval announced October 2, 2018.
Cariprazine Bipolar I Depression PDUFA FDA Approval announced May 28, 2019.
Ubrogepant Migraine Approved FDA Approval announced December 23, 2019.
Brimo DDS Geographic atrophy Phase 3 Phase 3 trial to be initiated 2H 2018.
Bimatoprost Open-angle glaucoma or ocular hypertension Approved FDA approval announced March 5, 2020.
AVYCAZ (ceftazidime and avibactam) Complicated Urinary Tract Infections (cUTI) - pediatric Approved FDA Approval announced March 18, 2019.
Botox Lower limb spasticity Approved FDA Approval announced October 24, 2019.
Botox Upper limb spasticity Approved FDA Approval announced June 21, 2019.
Presbysol Presbyopia Phase 3 Phase 3 top-line data due 2020.
Juvéderm VOLUMA Mid-Face Injection Via Cannula Approved FDA Approval announced September 3, 2019.
$1.81
-0.08  -4.23%
87.1 million
$157.6 million
04/07/2020
Tap to view 1 drug
Drug Indication Stage News
Twirla Contraceptive patch Approved FDA Approval announced February 14, 2020.
$3.20
-0.14  -4.19%
25.8 million
$82.4 million
04/07/2020
Tap to view 3 drugs
$2.62
-0.23  -8.07%
27.6 million
$72.4 million
0.12
04/07/2020
Tap to view 6 drugs
Drug Indication Stage News
Ampligen CFS CRL CRL February 4, 2013.
Ampligen, Intron A, celecoxib and pembrolizumab Triple-Negative Breast Cancer Phase 1 Phase 1 data due around 2Q 2020.
Ampligen, Intron A, and celecoxib Colorectal cancer Phase 2 Phase 2 interim data due around 2Q 2020.
Ampligen, cisplatin and pembrolizumab Ovarian cancer Phase 2 Phase 2 interim data due around 4Q 2020.
Ampligen, Intron A Prostate Cancer Phase 2 Phase 2 trial to commence enrolment in 4Q 2019.
Ampligen plus Intron A Ovarian cancer Phase 1/2 Phase 1 interim data to be presented 2020.
$14.81
+0.73  +5.18%
65 million
$963.3 million
04/07/2020
Tap to view 6 drugs
Drug Indication Stage News
AR101 ARTEMIS Peanut Allergy Phase 3 Phase 3 trial met primary endpoint - March 25, 2019.
AR101 RAMSES Peanut Allergy Phase 3 Phase 3 data released November 8, 2018 noted no serious adverse events
PALFORZIA - AR101 Peanut Allergy Approved FDA approval announced January 31, 2020.
AR 201 Egg Allergy Phase 2 Phase 2 trial to be completed 1H 2021.
AR101 with adjunctive dupilumab Peanut Allergy Phase 2 Phase 2 trial initiation announced October 15, 2018.
AR101 POSEIDON Peanut Allergy Phase 3 Phase 3 enrolment to be completed 2H 2020.
$6.70
-0.39  -5.50%
129.9 million
$870.1 million
04/07/2020
Tap to view 5 drugs
Drug Indication Stage News
Vadadustat - TRILO2GY Three-times-weekly dosing regimen for vadadustat Phase 3 Phase 3 trial to be initiated in 2019.
Auryxia Hyperphosphatemia Approved Approved Sept 5, 2014.
Vadadustat - INNO2VATE Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD) Phase 3 Phase 3 data due 2Q 2020.
Vadadustat - PRO2TECT Non-dialysis patients with anemia related to CKD (NDD-CKD) Phase 3 Phase 3 data due mid-2020.
Auryxia Iron deficiency anemia in non-dialysis dependent CKD patients Approved sNDA FDA Approval announced November 7, 2017.
$14.87
-0.88  -5.59%
101.1 million
$1.5 billion
04/07/2020
Tap to view 9 drugs
Drug Indication Stage News
AKCEA-ANGPTL3-LRx Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus Phase 2b Phase 2b data met primary endpoint - January 28, 2020.
AKCEA-APOCIII-LRx Hyperlipoproteinemia and established cardiovascular disease Phase 2 Phase 2 data met primary and secondary endpoints - January 22, 2020.
AKCEA-APO(a)-LRx Hyperlipoproteinemia(a) and established cardiovascular disease Phase 3 Phase 3 trial has been initiated - noted February 25, 2020.
Inotersen (IONIS-TTRRx) NEURO-TTR - familial amyloid polyneuropathy (FAP). Approved FDA Approval announced October 5, 2018,
Volanesorsen - APPROACH Familial chylomicronemia syndrome (FCS) CRL CRL issued August 27, 2018.
Volanesorsen Partial lipodystrophy rapidly Phase 3 Phase 3 initiated November 2015
Volanesorsen Familial partial lipodystrophy (FPL) Phase 3 Phase 3 data met primary endpoint - August 6, 2019.
AKCEA-TTR-LRx hATTR Amyloidosis Phase 3 Phase 3 trial initiation announced November 25, 2019.
AKCEA-TTR-LRx - CARDIO-TTRansform ATTR cardiomyopathy Phase 3 Phase 3 trial initiation announced January 10, 2020.
$19.80
-0.49  -2.41%
28.6 million
$566.4 million
04/07/2020
Tap to view 1 drug
$1.44
+0.04  +2.86%
28.7 million
$41.4 million
04/07/2020
Tap to view 4 drugs
Drug Indication Stage News
Nomacopan - CAPSTONE Paroxysmal nocturnal hemoglobinuria (PNH) Phase 3 Phase 3 interim data January 10, 2020 noted all patients achieved the primary endpoint of transfusion independence. Further data due at EHA June 11-14, 2020.
Nomacopan Atopic keratoconjunctivitis Phase 1/2 Phase 1/2 enrolment has paused due to COVID-19.
Nomacopan (Coversin) Bullous Pemphigoid Phase 2 Phase 2 full data due 2Q 2020.
Nomacopan Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) Phase 3 Phase 3 trial initiation announced December 23, 2019.
$14.89
-1.06  -6.65%
14.9 million
$222.5 million
04/07/2020
Tap to view 4 drugs
Drug Indication Stage News
Odevixibat (A4250) - PEDFIC- 1 Progressive familial intrahepatic cholestasis (PFIC) Phase 3 Phase 3 top-line data due mid-2020.
Elobixibat Nonalcoholic steatohepatitis (NASH) Phase 2 Phase 2 data due mid-2020.
Odevixibat (A4250) Biliary atresia Phase 3 Phase 3 trial planned for 1H 2020.
Odevixibat Alagille syndrome Phase 3 Phase 3 trial to commence by the end of 2020.
$2.12
-0.2  -8.62%
29.7 million
$62.9 million
04/07/2020
Tap to view 6 drugs
Drug Indication Stage News
ADX-102 - topical ocular reproxalap - RENEW Dry eye syndrome Phase 3 Phase 3 (Part 1) data December 3, 2019 noted one co-primary endpoint was met while the other missed. Part 2 to be initiated 2H 2020.
Reproxalap (ADX-102) - INVIGORATE Allergic conjunctivitis Phase 3 Phase 3 trial to be completed 2H 2020.
ADX-102 reproxalap Noninfectious anterior uveitis Phase 3 Phase 3 data did not meet endpoints - June 25, 2019.
Reproxalap (ADX-102) Sjögren-Larsson Syndrome (SLS) Phase 3 Development placed on hold - noted March 12, 2020.
ADX-1612 (ganetespib) Post-transplant lymphoproliferative disorder Phase 2 Development placed on hold - noted March 12, 2020.
ADX-2191 Proliferative vitreoretinopathy (PVR) Phase 3 Phase 3 enrolment to be completed in 2021.
$22.90
-0.53  -2.26%
79 million
$1.8 billion
04/07/2020
Tap to view 4 drugs
Drug Indication Stage News
AL001 Frontotemporal Dementia Phase 2 Phase 2 data to be presented in 2020.
AL002 Alzheimer’s disease Phase 1b Phase 1b proof of mechanism data due in 2020.
AL003 Alzheimer’s disease Phase 1 Phase 1b proof of mechanism data due in 2020.
AL101 Healthy volunteers Phase 1 Phase 1 initiation of dosing announced January 6, 2020.
$3.95
+0.03  +0.77%
5 million
$19.6 million
04/07/2020
Tap to view 1 drug
Drug Indication Stage News
Iluvien Diabetic macular edema Approved CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
$14.87
-0.28  -1.85%
158.5 million
$2.4 billion
04/07/2020
Tap to view 13 drugs
Drug Indication Stage News
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD) Schizophrenia Approved FDA approval announced July 2, 2018.
ALKS 3831 Schizophrenia, bipolar PDUFA PDUFA date November 15, 2020.
BYDUREON Type 2 diabetes Approved CRL received March 15, 2010.
Aristada Schizophrenia Approved Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Diroximel fumarate (BIIB098) Multiple sclerosis (MS) Approved FDA Approval announced October 30, 2019.
ALKS 6428 Opioid dependence Phase 3 Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 5461 Major depressive disorder CRL CRL announced February 1, 2019.
ALKS 3831 - ENLIGHTEN-1 Schizophrenia Phase 3 Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 4230 ARTISTRY-1 Solid tumors Phase 1 Phase 1/2 data at SITC November 2019 - 8/14 SD for monotherapy, 12/18 for combo (incl. 2 PRs).
Aristada and Invega Sustenna Schizophrenia Phase 3 Phase 3 data released April 9, 2019 - primary endpoint met.
ALKS 4230 + Keytruda - ARTISTRY-2 Solid tumors Phase 1 Phase 1 data presented at SITC November 8, 2019.
Diroximel fumarate (BIIB098) - Head-to-head trial versus Tecfidera - Relapsing Remitting Multiple Sclerosis (RRMS) Phase 3 Phase 3 top-line data met primary endpoint - July 30, 2019.
ALKS 4230 + Keytruda (ION-01) Head and neck squamous cell cancer Phase 2 Phase 2 trial to be initiated 4Q 2019.
$49.18
+1.03  +2.14%
48.7 million
$2.4 billion
04/07/2020
Tap to view 6 drugs
Drug Indication Stage News
AK002 Severe Allergic Conjunctivitis Phase 1b Phase 1b poster at AAAAI meeting March 15.
AK002 Indolent Systemic Mastocytosis Phase 1 Phase 1 data released February 19, 2019.
AK002 Chronic Urticaria Phase 2 Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.
Antolimab (AK002) Eosinophilic Gastritis Phase 3 Phase 3 trial initiation announced March 24, 2020.
Antolimab (AK002) Eosinophilic esophagitis Phase 2/3 Phase 2/3 trial initiation announced March 24, 2020.
Antolimab (subcutaneous) Healthy Volunteers Phase 1 Phase 1 trial initiation announced March 24, 2020.
$20.33
-0.78  -3.69%
124.9 million
$2.5 billion
04/07/2020
Tap to view 6 drugs
Drug Indication Stage News
UCART19 (PALL) Acute lymphoblastic leukemia (ALL) Phase 1 Recruitment halted due to COVID-19.
UCART19 - CALM Refractory B-cell Acute Lymphoblastic Leukaemia Phase 1 Recruitment halted due to COVID-19.
ALLO-715 - UNIVERSAL Multiple myeloma Phase 1/2 Phase 1/2 data due 4Q 2020.
ALLO-501 - ALPHA Non-Hodgkin lymphoma (NHL) Phase 1 Phase 1 initial data due 2Q 2020.
ALLO-715 with nirogacestat Multiple myeloma Phase 1 Phase 1 trial to commence 2H 2020.
ALLO-501A (ALPHA2) Phase 1 Phase 1 trial to be initiated 2Q 2020.
$0.96
-0.01  -1.20%
24.7 million
$23.8 million
04/07/2020
Tap to view 3 drugs
Drug Indication Stage News
Reloxaliase ALLN-177 (URIROX-1) Enteric Hyperoxaluria Phase 3 Phase 3 trial met primary endpoint, key secondary endpoint missed - November 7, 2019.
Reloxaliase ALLN-177 (Study 206) Primary hyperoxaluria Phase 2 Phase 2 presentation at ASN November 8, 2019.
Reloxaliase ALLN-177 (URIROX-2) Enteric Hyperoxaluria Phase 3 Phase 3 first sample size reassessment (SSR) due 3Q 2021.
$109.52
-2.62  -2.34%
113.1 million
$12.4 billion
04/07/2020
Tap to view 16 drugs
Drug Indication Stage News
Givosiran Acute hepatic porphyrias Approved FDA approval announced November 20, 2019.
Inclisiran - ORION-9 Hypercholesterolemia Phase 3 Phase 3 data met all endpoints - September 25, 2019. Data November 18, 2019 noted LDL-C reductions of 50%.
ALN-HBV02 (VIR-2218) Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 additional details due 2Q 2020.
Lumasiran (ALN-GO1) ILLUMINATE-A Primary Hyperoxaluria Type 1 (PH1) NDA Filing Completion of NDA filing announced April 7, 2020.
Patisiran Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Approved FDA Approval announced August 10, 2018.
ALN-CC5 (cemdisiran) IgA nephropathy Phase 2 Phase 2 trial ongoing.
Fitusiran (ATLAS) Hemophilia Phase 3 Phase 3 enrolment ongoing - February 6, 2020.
ALN-TTRsc02 - HELIOS-A ATTR amyloidosis Phase 3 Phase 3 completion of enrolment announced February 18, 2020. Top-line data due early 2021.
Inclisiran - ORION-10 Cardiovascular disease (ASCVD) Phase 3 Phase 3 data met all endpoints - September 25, 2019. Detailed data due at AHA noted 58% LDL-C lowering.
Inclisiran - ORION 11 Cardiovascular disease (ASCVD) Phase 3 Phase 3 trial met all primary and secondary efficacy endpoints. Noted September 2, 2019 a 54% LDL-C lowering after 11 months and 50% over 18 months.
ALN-AAT02 alpha-1 anti-trypsin deficiency-associated liver disease Phase 1/2 Phase 1/2 initial data released.
Lumasiran (ALN-GO1) ILLUMINATE-B Primary Hyperoxaluria Type 1 Phase 3 Phase 3 top-line data due mid-2020.
Patisiran APOLLO-B Wild-type ATTR amyloidosis patients with cardiomyopathy Phase 3 Phase 3 enrolment to be completed late-2020.
Lumasiran (ALN-GO1) ILLUMINATE-C Impaired renal function Phase 3 Phase 3 trial data due end of 2020.
ALN-AGT Hypertension Phase 1 Phase 1 trial ongoing.
ALN-TTRsc02 (vutrisiran) - HELIOS-B ATTR amyloidosis with cardiomyopathy Phase 3 Phase 3 trial has been initiated - noted November 22, 2019.
$2.78
+0.01  +0.36%
18.6 million
$51.7 million
04/07/2020
Tap to view 4 drugs
Drug Indication Stage News
N91115 Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein Phase 2 Phase 2 data released February 24, 2017 - primary endpoint not met.
ALPN-101 Healthy volunteers Phase 1 Phase 1 presentation at ASH December 8, 2019.
ALPN-202 Advanced Malignancies Phase 1 Phase 1 trial is open for enrolment - noted March 30, 2020.
ALPN-101 Graft Vs Host Disease Phase 1/2 Phase 1b/2 trial is open for enrolment - noted March 30, 2020.
$0.32
-0.04  -11.09%
27.8 million
$8.8 million
04/07/2020
Tap to view 5 drugs
Drug Indication Stage News
ALRN-6924 Peripheral T-cell lymphoma (PTCL) Phase 2a Noted that development to be discontinued - no pivotal trial.
ALRN-6924 and Cytarabine (Ara-C) Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS) Phase 1b Phase 1/1b trial ongoing.
ALRN-6924 and IBRANCE (palbociclib) Solid tumors Phase 2a Phase 2a final data due 2H 2020. Does not intend to further development.
ALRN-6924 and Paclitaxel Breast cancer Phase 1 Phase 1 has been initiated.
ALRN-6924 Small Cell Lung Cancer (SCLC) Phase 1/2 Phase 1b/2 proof of concept data due 4Q 2020.
$3.35
+0.38  +12.79%
15.4 million
$51.5 million
04/07/2020
Tap to view 6 drugs
Drug Indication Stage News
HepTCell Hepatitis B Phase 1 IND filing due 2020.
NasoVAX Flu vaccine Phase 2 Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.
NASOSHIELD Anthrax Phase 1b Phase 1b trial to be initiated in 1Q 2020.
ALT-801 Non-alcoholic steatohepatitis (NASH) Phase 1 Phase 1 trial to be initiated in 2020 with data due 2021.
Intranasal COVID-19 Vaccine Coronavirus COVID-19 Phase 1 Clinical trials to potentially commence in August 2020.
AdCOVID COVID-19 Coronavirus vaccine Phase 1 Phase 1 trial to be initiated in 3Q 2020.
$94.72
-1.19  -1.24%
222.1 million
$21 billion
04/07/2020
Tap to view 18 drugs
Drug Indication Stage News
CAEL‐101 AL amyloidosis Phase 2/3 Phase 2b/3 trial to be initiated 1H 2020 with data due in 2021.
ACH-4471 C3 glomerulopathy (C3G) Phase 2 Phase 2 completion due 2020.
Eculizumab Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Approved FDA Approval announced June 27, 2019.
ULTOMIRIS (ravulizumab-cwvz) atypical Hemolytic Uremic Syndrome (aHUS) Approved FDA Approval announced October 18, 2019.
ULTOMIRIS (ravulizumab-cwvz) Paroxysmal nocturnal hemoglobinuria (PNH) Approved FDA approval announced December 21, 2018.
Eculizumab Refractory generalized myasthenia gravis (gMG) Approved Approval announced October 23, 2017.
Danicopan (ACH-4471) Paroxysmal nocturnal hemoglobinuria (PNH) Phase 3 Phase 3 trial to be initiated early 2020.
ACH-5228 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1 Phase 2 trial planned to commence 1H 2020.
ALXN1840 (WTX101) Wilson disease Phase 3 Phase 3 top-line data due 1H 2021.
ULTOMIRIS (ravulizumab-cwvz) Generalized myasthenia gravis (gMG) Phase 3 Phase 3 trial initiated 1Q 2019.
ALXN1830 Warm autoimmune hemolytic anemia (WAIHA) Phase 1/2 Phase 2/3 trial to be initiated early 2020.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) Phase 3 Phase 3 PK data due 1H 2020.
Elamipretide Leber’s hereditary optic neuropathy (LHON) Phase 2 Phase 2 trial did not meet primary endpoint. Phase 3 trial planned for 2020.
Elamipretide Primary mitochondrial myopathy Phase 3 Phase 3 data did not meet primary endpoint - December 20, 2019.
ULTOMIRIS Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) Phase 3 Phase 3 trial to commence 1H 2020.
Eculizumab Generalized myasthenia gravis (gMG) - children Phase 3 Phase 3 trial has commenced - noted October 23, 2019.
Eculizumab Neuromyelitis Optica Spectrum Disorder (NMOSD) - children Phase 3 Phase 3 trial to commence 1Q 2020.
ULTOMIRIS (ravulizumab) - CHAMPION-ALS Amyotrophic lateral sclerosis (ALS) Phase 3 Phase 3 trial initiation due 1Q 2020.
$6.56
-0.11  -1.65%
34.3 million
$224.8 million
04/07/2020
Tap to view 6 drugs
Drug Indication Stage News
AMAG-423 / Digoxin immune fab (DIF) Severe preeclampsia in pregnant women Phase 2/3 Phase 2/3 top-line data due 1H 2020.
Vyleesi (Bremelanotide) Female sexual dysfunction (FSD) Approved FDA approval announced June 21, 2019.
Feraheme Adults with iron deficiency anemia (IDA) Approved Approval for sNDA filing announced February 5, 2018.
Makena - auto injector Reduce the risk of preterm birth in women with a singleton pregnancy Approved Approval announced February 14, 2018.
Makena Preterm birth Phase 3 Advisory Committee voted 9-7 recommending withdrawal from market - October 29, 2019.
Ciraparantag Anticoagulated reversal agent / Healthy volunteers Phase 2 End of Phase 2 trial meeting slated for 2H 2020.
AMGN Amgen Inc.
$208.78
-2.8  -1.32%
589.8 million
$123.1 billion
04/07/2020
Tap to view 35 drugs
Drug Indication Stage News
Tezepelumab - NAVIGATOR Asthma Phase 3 Phase 3 data due 2H 2020.
Prolia (denosumab) Glucocorticoid-induced osteoporosis (GIOP) Approved Approval announced May 21, 2018.
KYPROLIS (ASPIRE) Relapsed Multiple Myeloma Approved sNDA approval announced June 11, 2018.
Vectibix (Panitumumab) Wild-Type RAS Metastatic Colorectal Cancer Approved sBLA approval announced June 29, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) PDUFA Approved September 14, 2017.
Corlanor Chronic Heart Failure Approved Approved April 15, 2015.
Erenumab Migraine Approved Approval announced May 17, 2018.
OTEZLA Scalp Psoriasis PDUFA PDUFA date April 2020.
OTEZLA - PSA-006 Psoriatic Arthritis Phase 3 Phase 3 - primary endpoint met.
OTEZLA Behçet’s Disease Approved FDA Approval announced July 19, 2019.
Repatha Cardiovascular disease Approved Approval announced December 1, 2017.
XGEVA Multiple Myeloma Approved sBLA approval announced January 5, 2017.
KYPROLIS (ARROW) Multiple Myeloma Approved FDA approval announced October 1, 2018.
KYPROLIS (ENDEAVOR) Relapsed Multiple Myeloma Approved sNDA approved January 17, 2018.
BLINCYTO Ph+ R/R ALL Approved PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma BLA Filing BLA filing announced December 19, 2019.
ABP 980 (Kanjinti; trastuzumab-anns) Herceptin biosimilar CRL FDA approval announced June 13, 2019.
ABP 710 REMICADE biosimilar - rheumatoid arthritis Approved FDA Approval announced December 6, 2019.
Parsabiv Secondary hyperparathyroidism (SHPT) Approved Approved February 7, 2017.
EVENITY (Romosozumab) Osteoporosis Approved FDA Approval announced April 9, 2019.
Omecamtiv mecarbil GALACTIC-HF Acute heart failure Phase 3 Phase 3 top-line data due 4Q 2020.
Omecamtiv mecarbil METEORIC-HF Acute heart failure Phase 3 Phase 3 enrolment to be completed in 2020.
AMG 420 Relapsed. Refractory (R/R) Multiple Myeloma (MM) Phase 1 Phase 1 data ASCO June 2, 2019. Overall response rate 70% (7/10) in high dose, 13/42 response across all cohorts.
AMG 330 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Phase 1 Phase 1 data at ASH December 1, 2018 noted 12.5% ORR.
Nplate (Romiplostim) Immune Thrombocytopenia (Pediatric) Approved FDA approval announced December 14, 2018.
Nplate (Romiplostim) Immune thrombocytopenia (ITP) Approved FDA Approval announced October 18, 2019.
KYPROLIS (CANDOR) Multiple Myeloma sNDA Filing sNDA filed January 2020.
OTEZLA Psoriasis Phase 3 Phase 3 data due mid-2020.
AMG 594 Healthy volunteers Phase 1 Phase 1 SAD/MAD cohorts to be completed 2H 2020.
AMG 510 Solid tumors Phase 1 Phase 1 update at ESMO noted 54% PR rate for NSCLC patients (960mg); 1/12 for CRC patients. Next update due in 2020.
CNP520 Alzheimer’s Disease Phase 2/3 Phase 2/3 trial discontinued due to lack of efficacy.
BLINCYTO Acute lymphoblastic leukemia (ALL) - pediatric Phase 3 Phase 3 enrolment terminated due to treatment benefit over chemo. Primary endpoint of event-free survival met.
AMG 570 Systemic Lupus Erythematosus (SLE) Phase 2 Phase 2 trial is enrolling.
Tezepelumab Chronic obstructive pulmonary disease (COPD) Phase 2 Phase 2 trial is enrolling.
AMG 510 Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 2 monotherapy data due 2020.
$0.47
-0.01  -2.05%
158.8 million
$74.5 million
13.67
04/07/2020
Tap to view 2 drugs
Drug Indication Stage News
Ampion Osteoarthritis of the Knee Phase 3 Phase 3 enrolment has been suspended - noted March 24, 2020.
Optina Diabetic Macula Edema Phase 2b Phase 2b data released May 2015 did not meet endpoints
$14.91
-0.7  -4.48%
46.2 million
$689.4 million
04/07/2020
Tap to view 3 drugs
Drug Indication Stage News
Albuterol DPI Asthma Phase 2b
Naloxone Intranasal Opioid overdose CRL CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol) Asthma CRL CRL issued December 27, 2016.
$5.04
+0.24  +5.00%
361.2 million
$1.8 billion
04/07/2020
Tap to view 1 drug
Drug Indication Stage News
Vascepa High Triglycerides With Mixed Dyslipidemia Approved FDA Approval announced December 13, 2019.
$2.91
-0.23  -7.32%
311.7 million
$907.2 million
3.01
04/07/2020
Tap to view 2 drugs
Drug Indication Stage News
IPX203 Parkinson's disease Phase 3 Phase 3 trial ongoing.
K127 Myasthenia Gravis NDA Filing NDA filing planned.
$14.07
-1.19  -7.80%
27.3 million
$383.6 million
04/07/2020
Tap to view 5 drugs
Drug Indication Stage News
ANB020 - etokimab Moderate-to-severe adult atopic dermatitis Phase 2b Phase 2b data failed to meet primary endpoint - November 8, 2019.
ANB020 - etokimab Severe adult eosinophilic asthma Phase 2a Phase 2b trial initiation postponed.
ANB019 - POPLAR Palmo-plantar pustular psoriasis Phase 2 Phase 2 data due 2H 2020.
ANB019 Generalized pustular psoriasis Phase 2 Phase 2 interim data on first TWO patients announced September 30, 2019 with patients reaching primary endpoint. Further data due 2020.
ANB020 - etokimab Nasal polyps Phase 2 Phase 2 data due 1H 2020.
$0.72
+0.02  +2.34%
7.4 million
$5.3 million
04/07/2020
Tap to view 2 drugs
Drug Indication Stage News
Inodiftagene - Codex Non-muscle invasive bladder cancer (NMIBC) Phase 2 Phase 2 trial discontinued due to lack of efficacy - November 15, 2019.
Inodiftagene with BCG - Leo Non-muscle invasive bladder cancer (NMIBC) Phase 3 Phase 3 planned for 4Q 2019 or 1Q 2020.
$28.11
-0.98  -3.37%
14.2 million
$398.3 million
04/07/2020
Tap to view 3 drugs
Drug Indication Stage News
Cingal Osteoarthritis Phase 3 Phase 3 trial did not meet primary endpoint - June 19, 2018. Further trial to be initiated 1H 2020.
Monovisc Osteoarthritis Approved Approved Feb 2014
HYALOFAST Cartilage defects of the knee Phase 3 Phase 3 enrollment to be completed by the end of 2018.
$1.68
+0.06  +3.70%
21 million
$35.3 million
04/07/2020
Tap to view 1 drug
Drug Indication Stage News
Breast cancer vaccine Phase 1
$2.95
+0.13  +4.61%
6.8 million
$20.2 million
0.13
04/07/2020
Tap to view 2 drugs
Drug Indication Stage News
ANVS401 Alzheimer’s disease Phase 2a Phase 2a interim data due 4Q 2020.
ANVS401 Parkinson’s disease Phase 2a Phase 2a trial ongoing.
$25.51
-1.6  -5.90%
75.3 million
$1.9 billion
04/07/2020
Tap to view 6 drugs
Drug Indication Stage News
APL-2 subcutaneous Cold agglutinin disease (CAD) Phase 2 Phase 3 trial plan update due 1H 2020.
APL-2 OAKS Geographic atrophy (GA) associated with age-related macular degeneration (AMD) Phase 3 Phase 3 enrolment to be completed 1Q 2020.
APL-2 subcutaneous PEGASUS Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 3 Phase 3 data met primary endpoint - January 7, 2020. 48-week data due 2Q 2020.
APL-2 PADDOCK Paroxysmal Nocturnal Hemoglobinuria Phase 1